Human BioSystems Submits SB-2 Registration Statement to the SEC for the Exchange of Reg S Shares Into Registered Shares
MONDAY, JUNE 05, 2006 7:00 AM
- CCNMatthews
PALO ALTO, CALIFORNIA, Jun 5, 2006 (CCNMatthews via COMTEX) -- Human BioSystems (HBS) (HBSC) , a developer of preservation platforms for organs and other biomaterials, specializing in the development of proprietary above zero ("HBS-AZ") and below zero ("HBS-BZ") organ and tissue preservation systems and methods for preserving blood platelets, announced a proposed offering of up to 10,500,000 shares of common stock by certain shareholders who obtained the stock in an earlier exchange offer pursuant to Regulation S promulgated under the Securities Act of 1933, as amended. HBS has filed with the Securities and Exchange Commission a registration statement relating to the proposed offering. HBS will not sell any shares of common stock in this offering, nor will it receive any proceeds from it.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.
HBS is headquartered in Palo Alto, California, with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, ability to reproduce study results in humans, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
SOURCE: Human BioSystems
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Copyright (C) 2006 CCNMatthews. All rights reserved
My posts are not buy or sell recommendations. I may buy, sell,own, go long and short on stocks I post about.
DO YOUR DD!
AI
